Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 5/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3061690 | 1.00 | HDAC2 (0.51) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL13177815 | 0.89 | LMNA (0.57) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL3056373 | 0.89 | HDAC2 (0.50) | HDAC2 | |
| SCHEMBL8075531 | 0.89 | HDAC2 (0.50) | HDAC2 | |
| SCHEMBL3053732 | 0.89 | HDAC1 (0.50) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL8069434 | 0.89 | HDAC1 (0.50) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL3044179 | 0.88 | HDAC1 (0.58) | HDAC2HDAC1 | |
| SCHEMBL13136776 | 0.88 | HDAC1 (0.58) | HDAC2HDAC1 | |
| SCHEMBL8081889 | 0.86 | LMNA (0.62) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL3053166 | 0.86 | LMNA (0.62) | HDAC2HDAC1HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476255-B2 | Histone deacetylase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-07-02 | — | — | US | disclosed |
| US-20100222379-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| WO-2009047615-A2 | NOVEL HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222379-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | HDAC5, HDAC2, HDAC1 | HDAC2 2/4885HDAC1 3/4885HDAC3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.